Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study
Jennifer Donnan,1 Rita Huang,1 Laurie Twells2 1School of Pharmacy, Memorial University, St. John’s, Newfoundland and Labrador, Canada; 2Faculty of Medicine, Memorial University, St. John’s, Newfoundland and Labrador, CanadaCorrespondence: Jennifer Donnan, Tel +1 709 864-3587, Email Jennifer.donnan@m...
Main Authors: | , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Medical Press
2022
|
Subjects: | |
Online Access: | https://doaj.org/article/321d60cf72f8493e921b2db201eae960 |
id |
ftdoajarticles:oai:doaj.org/article:321d60cf72f8493e921b2db201eae960 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:321d60cf72f8493e921b2db201eae960 2023-05-15T17:22:03+02:00 Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study Donnan J Huang R Twells L 2022-04-01T00:00:00Z https://doaj.org/article/321d60cf72f8493e921b2db201eae960 EN eng Dove Medical Press https://www.dovepress.com/patient-preferences-for-attributes-of-health-canada-approved-weight-lo-peer-reviewed-fulltext-article-PPA https://doaj.org/toc/1177-889X 1177-889X https://doaj.org/article/321d60cf72f8493e921b2db201eae960 Patient Preference and Adherence, Vol Volume 16, Pp 911-923 (2022) patient preferences obesity weight loss anti-obesity medications canada Medicine (General) R5-920 article 2022 ftdoajarticles 2022-12-30T22:03:40Z Jennifer Donnan,1 Rita Huang,1 Laurie Twells2 1School of Pharmacy, Memorial University, St. John’s, Newfoundland and Labrador, Canada; 2Faculty of Medicine, Memorial University, St. John’s, Newfoundland and Labrador, CanadaCorrespondence: Jennifer Donnan, Tel +1 709 864-3587, Email Jennifer.donnan@mun.caPurpose: Obesity is a complex disease with negative impacts on physical and mental health. The treatment of obesity is an area where shared decision making and patient preferences play an important role. Recommendations surrounding weight loss medications are evolving and only recently, with the publication of the 2020 Canadian Obesity Management Clinical Guidelines, pharmacotherapy has become a recommended alternative for obesity management. Guidelines recommend three medications: orlistat, liraglutide, and naltrexone/bupropion. This study sought to identify medication attributes relevant to patients starting pharmacotherapy for weight management.Patients and Methods: Semi-structured focus groups and interviews were conducted with Canadian residents who were ≥ 18 years of age and were living with obesity (body mass index [BMI] ≥ 30kg/m2 or ≥ 27kg/m2 with adiposity-related complications). Sessions were conducted virtually, audio recorded, and transcribed. Two team members used a combination of inductive and deductive coding to independently code the data. A final coding template was agreed upon through discussion.Results: A total of 21 individuals participated (85.7% female, 76.2% ≥ 40 years of age) with the average BMI being 44.3 kg/m2. Participants touched upon many attributes which were categorized into five categories: 1) cost, 2) regimen, 3) side effects, 4) benefits, and 5) non-medication attributes. Cost of medications, lack of coverage by insurance companies, and stigma were identified as major barriers to accessing medications. There was consensus in the desire for a simple regimen, however there was heterogeneity among opinions on tolerability of side effects, desired benefits, and route of ... Article in Journal/Newspaper Newfoundland Directory of Open Access Journals: DOAJ Articles Newfoundland Canada Laurie ENVELOPE(-44.616,-44.616,-60.733,-60.733) |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
patient preferences obesity weight loss anti-obesity medications canada Medicine (General) R5-920 |
spellingShingle |
patient preferences obesity weight loss anti-obesity medications canada Medicine (General) R5-920 Donnan J Huang R Twells L Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study |
topic_facet |
patient preferences obesity weight loss anti-obesity medications canada Medicine (General) R5-920 |
description |
Jennifer Donnan,1 Rita Huang,1 Laurie Twells2 1School of Pharmacy, Memorial University, St. John’s, Newfoundland and Labrador, Canada; 2Faculty of Medicine, Memorial University, St. John’s, Newfoundland and Labrador, CanadaCorrespondence: Jennifer Donnan, Tel +1 709 864-3587, Email Jennifer.donnan@mun.caPurpose: Obesity is a complex disease with negative impacts on physical and mental health. The treatment of obesity is an area where shared decision making and patient preferences play an important role. Recommendations surrounding weight loss medications are evolving and only recently, with the publication of the 2020 Canadian Obesity Management Clinical Guidelines, pharmacotherapy has become a recommended alternative for obesity management. Guidelines recommend three medications: orlistat, liraglutide, and naltrexone/bupropion. This study sought to identify medication attributes relevant to patients starting pharmacotherapy for weight management.Patients and Methods: Semi-structured focus groups and interviews were conducted with Canadian residents who were ≥ 18 years of age and were living with obesity (body mass index [BMI] ≥ 30kg/m2 or ≥ 27kg/m2 with adiposity-related complications). Sessions were conducted virtually, audio recorded, and transcribed. Two team members used a combination of inductive and deductive coding to independently code the data. A final coding template was agreed upon through discussion.Results: A total of 21 individuals participated (85.7% female, 76.2% ≥ 40 years of age) with the average BMI being 44.3 kg/m2. Participants touched upon many attributes which were categorized into five categories: 1) cost, 2) regimen, 3) side effects, 4) benefits, and 5) non-medication attributes. Cost of medications, lack of coverage by insurance companies, and stigma were identified as major barriers to accessing medications. There was consensus in the desire for a simple regimen, however there was heterogeneity among opinions on tolerability of side effects, desired benefits, and route of ... |
format |
Article in Journal/Newspaper |
author |
Donnan J Huang R Twells L |
author_facet |
Donnan J Huang R Twells L |
author_sort |
Donnan J |
title |
Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study |
title_short |
Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study |
title_full |
Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study |
title_fullStr |
Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study |
title_full_unstemmed |
Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study |
title_sort |
patient preferences for attributes of health canada approved weight loss medications among adults living with obesity in canada: a qualitative study |
publisher |
Dove Medical Press |
publishDate |
2022 |
url |
https://doaj.org/article/321d60cf72f8493e921b2db201eae960 |
long_lat |
ENVELOPE(-44.616,-44.616,-60.733,-60.733) |
geographic |
Newfoundland Canada Laurie |
geographic_facet |
Newfoundland Canada Laurie |
genre |
Newfoundland |
genre_facet |
Newfoundland |
op_source |
Patient Preference and Adherence, Vol Volume 16, Pp 911-923 (2022) |
op_relation |
https://www.dovepress.com/patient-preferences-for-attributes-of-health-canada-approved-weight-lo-peer-reviewed-fulltext-article-PPA https://doaj.org/toc/1177-889X 1177-889X https://doaj.org/article/321d60cf72f8493e921b2db201eae960 |
_version_ |
1766108292063428608 |